Compounds > apomorphine
Page last updated: 2024-08-17

apomorphine and Disease Exacerbation

apomorphine has been researched along with Disease Exacerbation in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (21.74)18.2507
2000's4 (17.39)29.6817
2010's11 (47.83)24.3611
2020's3 (13.04)2.80

Authors

AuthorsStudies
Larson, D; Simuni, T1
Mariani, LL1
Müller, T1
Liu, L; Wang, X; Zhang, L; Zhang, W1
Airavaara, M; Bäck, S; Huotarinen, A; Julku, U; Laakso, A; Männistö, PT; Penttinen, AM; Piepponen, TP; Saarma, M; Tuominen, R; Voutilainen, MH1
Antonini, A; Jenner, P1
Jiang, L; Long, K; Lu, F; Qu, J; Schaeffel, F; Stell, WK; Ying, H; Zheng, Y; Zhou, X1
Chen, NH; Chu, SF; Li, J; Liu, Y; Song, LK; Sun, JD; Yuan, YH1
Defebvre, L; Moreau, C1
Antonutti, L; Capus, L; Ferigo, L; Pizzolato, G; Simonetto, M; Zanet, L; Zorzon, M1
Krauss, JK; Lütjens, G; Schwabe, K1
Chen, JJ; Chen, LH; Chiang, PT; Hsieh, TH; Lee, HY1
Fernandez, HH1
Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M1
Kulisevsky, J; Martí, MJ1
Caudle, WM; Cohen, AD; Miller, GW; Schallert, T; Tillerson, JL; Zigmond, MJ1
Eggert, K; Möller, JC; Oertel, WH; Sommer, N; Tackenberg, B1
Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K1
Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K1
Dougherty, PM; Hallett, M; Karp, BI; Lenz, FA; Metman, LV; Reich, SG; Rowland, LH; Suarez, JI1
Hughes, AJ1
Almaguer, M; Hunter, C; Jankovic, J; Ondo, W1

Reviews

6 review(s) available for apomorphine and Disease Exacerbation

ArticleYear
New dopaminergic therapies for PD motor complications.
    Neuropharmacology, 2022, 02-15, Volume: 204

    Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease

2022
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:14

    Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dopamine Agonists; Humans; Injection Site Reaction; Injections, Subcutaneous; Levodopa; Parkinson Disease; Subcutaneous Tissue

2020
[Medical and surgical treatment of Parkinson's disease].
    Presse medicale (Paris, France : 1983), 2017, Volume: 46, Issue:2 Pt 1

    Topics: Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Foreign-Body Reaction; Humans; Intracranial Hemorrhages; Monoamine Oxidase Inhibitors; Mood Disorders; Parkinson Disease; Patient Selection; Quality of Life

2017
Updates in the medical management of Parkinson disease.
    Cleveland Clinic journal of medicine, 2012, Volume: 79, Issue:1

    Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease

2012
[Candidate patient for treatment with continuous apomorphine infusion].
    Revista de neurologia, 2012, Volume: 55 Suppl 1

    Topics: Aged; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Cognition Disorders; Contraindications; Depression; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Hallucinations; Humans; Infusions, Intravenous; Middle Aged; Parkinson Disease; Patient Selection; Psychoses, Substance-Induced; Psychotic Disorders

2012
Apomorphine test in the assessment of parkinsonian patients: a meta-analysis.
    Advances in neurology, 1999, Volume: 80

    Topics: Apomorphine; Disease Progression; Dopamine Agonists; Humans; Parkinson Disease; Parkinson Disease, Secondary

1999

Trials

2 trial(s) available for apomorphine and Disease Exacerbation

ArticleYear
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

1998
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:4

    Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease; Time Factors; Treatment Outcome

1999

Other Studies

15 other study(ies) available for apomorphine and Disease Exacerbation

ArticleYear
[Continuous and advanced treatment strategies in the old to very old parkinsonian population].
    Geriatrie et psychologie neuropsychiatrie du vieillissement, 2020, 06-01, Volume: 18, Issue:2

    Topics: Advance Care Planning; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Continuity of Patient Care; Deep Brain Stimulation; Disease Progression; Dopamine; Female; Frail Elderly; Humans; Long-Term Care; Male; Parkinson Disease; Quality of Life; Thalamus; Treatment Outcome

2020
Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
    Behavioural brain research, 2017, 06-15, Volume: 328

    Topics: Animals; Apomorphine; Diffusion Tensor Imaging; Disease Progression; Dopamine Agonists; Gliosis; Immunohistochemistry; Magnetic Resonance Imaging; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase

2017
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
    Neuroscience, 2018, 03-15, Volume: 374

    Topics: Animals; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Humans; Male; Motor Activity; Nerve Growth Factors; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Recombinant Proteins; Tyrosine 3-Monooxygenase

2018
Apomorphine infusion in advanced Parkinson disease.
    Nature reviews. Neurology, 2018, Volume: 14, Issue:12

    Topics: Apomorphine; Disease Progression; Dopamine Agonists; Drug Delivery Systems; Humans; Infusions, Subcutaneous; Parkinson Disease

2018
Effects of dopaminergic agents on progression of naturally occurring myopia in albino guinea pigs (Cavia porcellus).
    Investigative ophthalmology & visual science, 2014, Sep-30, Volume: 55, Issue:11

    Topics: Animals; Apomorphine; Benzazepines; Disease Models, Animal; Disease Progression; Dopamine Agonists; Dopamine Antagonists; Follow-Up Studies; Guinea Pigs; Myopia; Refraction, Ocular; Sulpiride; Treatment Outcome

2014
Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
    Behavioural brain research, 2015, Nov-01, Volume: 294

    Topics: alpha-Synuclein; Animals; Apomorphine; Body Weight; Brain; Disease Progression; Dopamine; Dopamine Agonists; Enteric Nervous System; Environmental Exposure; Housing, Animal; Male; Mice, Inbred C57BL; Motor Activity; Muscle, Skeletal; Neurons; Olfactory Perception; Parkinsonian Disorders; Rotenone; Tyrosine 3-Monooxygenase

2015
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29, Issue:3

    Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Disease Progression; Dopamine Agonists; Drug Resistance; Fever; Humans; Male; Ondansetron; Parkinson Disease; Respiratory Insufficiency; Serotonin Antagonists; Syndrome; Treatment Outcome

2008
Lesions of the entopeduncular nucleus in rats prevent apomorphine-induced deficient sensorimotor gating.
    Behavioural brain research, 2011, Jul-07, Volume: 220, Issue:2

    Topics: Acoustic Stimulation; Analysis of Variance; Animals; Apomorphine; Conditioning, Operant; Disease Models, Animal; Disease Progression; Dopamine Agonists; Entopeduncular Nucleus; Gait Disorders, Neurologic; Inhibition, Psychological; Male; Maze Learning; Motor Activity; Rats; Rats, Sprague-Dawley; Reflex, Startle; Rotarod Performance Test

2011
Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
    Behavioural brain research, 2011, Sep-12, Volume: 222, Issue:1

    Topics: Analysis of Variance; Animals; Apomorphine; Disease Models, Animal; Disease Progression; Functional Laterality; Gait Disorders, Neurologic; Male; Medial Forebrain Bundle; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Wistar; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase; Videotape Recording

2011
Subthalamic activity during diphasic dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:9

    Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm

2012
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Aug-01, Volume: 22, Issue:15

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surgical; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Forelimb; Homovanillic Acid; Membrane Glycoproteins; Membrane Transport Proteins; Movement; Nerve Tissue Proteins; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Physical Exertion; Rats; Rats, Long-Evans; Restraint, Physical; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins

2002
Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:1

    Topics: Acute Disease; Aged; Anemia; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Hematoma; Humans; Hypokinesia; Infusions, Parenteral; Leukocytosis; Male; Parkinson Disease; Pneumonia, Pneumococcal; Radiography; Rectus Abdominis

2006
[Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
    Krankenpflege Journal, 2005, Volume: 43, Issue:7-10

    Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Neurologic Examination; Parkinson Disease

2005
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Neurology, 1998, Volume: 50, Issue:2

    Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Humans; Levodopa; Motor Activity; Parkinson Disease

1998
Pallidal activity during dystonia: somatosensory reorganisation and changes with severity.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 65, Issue:5

    Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dystonia; Female; Globus Pallidus; Humans; Middle Aged; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index

1998